Poly(ADP‐Ribose) Polymerase (PARP) Inhibitors for locally advanced or metastatic breast cancer
Referencias
Additional references
Altman DG. Systematic reviews of evaluations of prognostic variables. BMJ 2001;323(7306):228‐47.
Cox DR. Regression models and life tables. Journal of the Royal Statistical Society 1972;34(2):187‐220.
Foulkes WD, Smith IE, Reis‐Filho JS. Triple‐negative breast cancer. New England Journal of Medicine 2010;363(20):1938‐48.
McMaster University. GRADEprofiler (GRADEpro). McMaster University, 2014.
Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Khasraw M, Robson M. Poly (ADP‐ribose) polymerase inhibitors in breast cancer and other tumors: advances and challenges. Clinical Investigation 2011;1(11):1545‐54.
Machin D, Stenning SP, Parmar MKP. Thirty years of Medical Research Council randomized trials in solid tumors. Journal of Clinical Oncology 1997;9:100‐14.
Parmar MKB, Torri V, Steward L. Extracting summary statistics to perform meta‐analysis of the published literature for survival endpoints. Statistics in Medicine 1998;17:2815‐34.
Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000;406(6797):747‐52.
The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. Journal of the National Cancer Institute 2000;92(3):205‐16.
